Predictive financial models and market consensus projections for Outlook Therapeutics stock during 2026 estimate trading ranges fluctuating around $0.60 to $1.00 per share, heavily dependent on commercial execution milestones, quarterly sales reports, and broader investor sentiment surrounding micro-cap biotechnology equities.